跳至主要内容
临床试验/JPRN-UMIN000004088
JPRN-UMIN000004088已完成未知

Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC - Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC

Saitama Medical University0 个研究点目标入组 50 人开始时间: 2010年8月27日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • The following patients were excluded 1)Allegic history to interferon preparations 2)Autoimmune hepatitis,alcoholic liver injury,or chronic liver diseases with other underlying causes 3)Liver cirrhosis,decompensated liver diseases 4) Abnormal thyroid function 5)Concomitant herbal medication of Sho-saikoto 6) history of interstitial pneumonia 7) Women of childbearing potential and pregnancy, lactating woman 8)severe depression 9)Allergic to vaccine or biological preparations 10)Other conditions considered inappropriate by attending physician

研究者

相似试验